Sugi Predict

Sugi Predict / Compounds / SCHEMBL12017809

SCHEMBL12017809

SCHEMBL12017809

CC(=O)C1CC(OCc2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.49
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ OPRM1 P35372 2/20 0.43
▸ OPRL1 P41146 2/20 0.43
▸ AGTR2 P50052 2/20 0.43
▸ EPHX2 P34913 1/20 0.43
▸ MAOB P27338 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ TMEM97 Q5BJF2 1/20 0.41
▸ CARM1 Q86X55 1/20 0.41
▸ PRMT6 Q96LA8 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ PRMT8 Q9NR22 1/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.41
▸ NAAA Q02083 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL582677 0.86 NPC1 (0.49) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL8347290 0.86 NPC1 (0.49) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL871908 0.86 NPC1 (0.49) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL2452190 0.85 OPRM1 (0.49) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL2449563 0.85 OPRM1 (0.49) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL2776825 0.85 OPRM1 (0.49) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL8352380 0.85 ALDH1A1 (0.50) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL8353490 0.85 ALDH1A1 (0.50) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL1588250 0.85 ALDH1A1 (0.50) ALDH1A1CTSLCTSBCTSKOPRM1
SCHEMBL21910067 0.84 CTSL (0.43) ALDH1A1CTSLCTSBCTSKAGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743079-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 — — EP disclosed
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
WO-2025015106-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
EP-4225435-B1 AMINOIMIDAZOLE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2024-12-11 — — EP disclosed
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-11-07 — — US disclosed
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
EP-4288426-A1 QUINOXALINE DERIVATIVES AND USES THEREOF Black Diamond Therapeutics, Inc. (US) 2023-12-13 — — EP disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
EP-3419978-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2019-01-02 — — EP disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20120220624-A1 PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 ALDH1A1 3550/4885CTSL 2418/4885CTSB 3943/4885
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF APOL1, APOB, LDLR ALDH1A1 1201/4885CTSL 95/4885CTSB 452/4885
US-20120220624-A1 PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS CDK1, CDK5, TTBK1 ALDH1A1 3446/4885CTSL 3505/4885CTSB 2856/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 ALDH1A1 1666/4885CTSL 3281/4885CTSB 3830/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 ALDH1A1 3564/4885CTSL 2468/4885CTSB 3891/4885
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF NQO2, NQO1, GLS ALDH1A1 701/4885CTSL 2308/4885CTSB 2608/4885
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 ALDH1A1 3564/4885CTSL 2468/4885CTSB 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.